Bisphosphonate-related osteonecrosis of the jaw: an Italian post-marketing surveillance analysis

Bibliography

• Pozzi S, Raje N. The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist 2011;13:651-62
   Google Scholar
• Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222s-30s
   PubMed Web of Science ®Google Scholar
• Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9(Suppl 4):28-37
   PubMed Web of Science ®Google Scholar
• Haworth AE, Webb J. Skeletal complications of bisphosphonate use: what the radiologist should know. Br J Radiol 2012;85:1333-42
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Einhorn TA. Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures. Bone 2012;50:1196-200
   PubMed Web of Science ®Google Scholar
• Kühl S, Walter C, Acham S, et al. Bisphosphonate-related osteonecrosis of the jaws-a review. Oral Oncol 2012;48:938-47
   PubMed Web of Science ®Google Scholar
• Solomon DH, Mercer E, Woo SB, et al. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int 2012;24:237-44
   PubMed Web of Science ®Google Scholar
• McLeod NM, Brennan PA, Ruggiero SL. Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review. Surgeon 2012;10:36-42
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Medicines Agency 2013 priorities for drug safety research. Long term adverse skeletal effects of bisphosphonate. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/05/WC500127478.pdf [Last accessed 24 February 2014]
   Google Scholar
• Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008;9:1166-72
   PubMed Web of Science ®Google Scholar
• Krüger TB, Sharikabad MN, Herlofson BB. Bisphosphonate-related osteonecrosis of the jaw in four Nordic countries and an indication of under-reporting. Acta Odontol Scand 2013;71:1386-90
   PubMed Web of Science ®Google Scholar
• Parretta E, Ianniello B, Ferrazin F, et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. Vaccine 2011;29:3708-13
   PubMed Web of Science ®Google Scholar
• Mozzicato P. Standardised MedDRA queries: their role in signal detection. Drug Saf 2007;30:617-19
   PubMed Web of Science ®Google Scholar
• Assouline-Dayan Y, Chang C, Greenspan A et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002;32:94-124
   PubMed Web of Science ®Google Scholar
• Landesberg R, Woo V, Cremers S, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci 2011;1218:62-79
   PubMed Web of Science ®Google Scholar
• American Association of Oral and Maxillofacial Surgeons. Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw. 2009. Available from: http://www.aaoms.org/docs/position_papers/bronj_update.pdf [Accessed 05 May 10 2013]
   Google Scholar
• European Medicines Agency CHMP assessment report on Bisphosphonates and osteonecrosis of the jaw. 2004. Availble from http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500051428.pdf [Accessed 10 February 2014]
   Google Scholar
• Migliorati CA, Woo SB, Hewson I, et al. Bisphosphonate Osteonecrosis Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) (2010) A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 2010;18:1099-106
   PubMed Web of Science ®Google Scholar
• Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136:1117-24
   PubMed Web of Science ®Google Scholar
• Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to osteonecrosis development. Oncologist 2009;14:1154-66
   Google Scholar
• Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102
   PubMed Web of Science ®Google Scholar
• Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75
   PubMed Web of Science ®Google Scholar
• Diniz-Freitas M, López-Cedrún JL, Fernández-Sanromán J, et al. Oral bisphosphonate-related osteonecrosis of the jaws: clinical characteristics of a series of 20 cases in Spain. Med Oral Patol Oral Cir Bucal 2012;17:e751-8
   PubMed Web of Science ®Google Scholar
• Crépin S, Laroche ML, Sarry B, et al. Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review. Eur J Clin Pharmacol 2010;66:547-54
   PubMed Web of Science ®Google Scholar
• Sittig HB. Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate. Onkologie 2012;35:380-7
   PubMed Web of Science ®Google Scholar
• Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59
   PubMed Web of Science ®Google Scholar
• Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209-57
   PubMed Web of Science ®Google Scholar
• Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37
   PubMed Web of Science ®Google Scholar
• Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52
   PubMed Web of Science ®Google Scholar
• Ibrahim T, Barbanti F, Giorgio-Marrano G, et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist 2008;13:330-6
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91
   PubMed Web of Science ®Google Scholar
• Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 2006;2006:356-60
   Google Scholar
• Dickinson M, Prince HM, Kirsa S, et al. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Intern Med J 2009;39:304-16
   PubMed Web of Science ®Google Scholar
• Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today 2009;14:343-57
   PubMed Web of Science ®Google Scholar
• Pal SN, Duncombe C, Falzon D, et al. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf 2013;36:75-81
   PubMed Web of Science ®Google Scholar
• Ruggiero S, Rafaniello C, Bravaccio C, et al. Safety of attention Deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. J Child Adolesc Psychopharmacol. 2012;22:415-22
   Google Scholar
• Ferrajolo C, Capuano A, Verhamme KM, et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010;70:721-8
   PubMed Web of Science ®Google Scholar